IP Library Granted Patent US 7,517,667
Granted Patent B2
US 7,517,667 · App. 11/214,997 · Granted Apr 14, 2009

Methods for promoting, inhibiting and detecting toxin entry into cells

Assignee: Boston Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,517,667
App. No.
11/214,997
Granted
Apr 14, 2009
Kind
B2
Abstract

In vitro delivery of the diphtheria toxin (DT) catalytic (C) domain from the lumen of purified early endosomes to the external milieu requires the addition of both ATP and a cytosolic translocation factor (CTF) complex. The results presented here demonstrate that β-COP plays an essential role in the cytosolic release of the C-domain and is mediated by a consensus peptide sequence found on several bacterial toxins and in HIV-1 reverse transcriptase. The invention features methods for inhibiting cell death that include the administration of compounds based on this consensus sequence that inhibit the translocation of the catalytic domain of toxins or transcription factors. Also featured are methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death by blocking or accelerating, respectively, the rate of toxin/factor endosomal translocation.

Claims (34)

1. A method of identifying a compound that is capable of inhibiting cell death in a mammal comprising the following steps:

a) isolating, from a mammalian cell, an early endosome comprising a toxin selected from the group consisting of Diptheria toxin, Botulinum toxin, Anthrax toxin Lethal Factor (LF), and Anthrax toxin Edema Factor (EF);

b) placing said endosomes in a cytosolic buffer;

c) contacting said endosomes with a cytosolic translocation factor complex, comprising beta-COP;

d) contacting said endosomes with said compound;

e) acidifying said endosome; and

f) measuring translocation of said toxin, wherein a decreased level of said translocation relative to that observed in the absence of said compound indicates that said compound is capable of inhibiting said cell death.

2. The method of claim 1 , wherein said toxin is a fusion protein comprising IL-2.

3. The method of claim 2 , wherein said toxin is DAB 389 IL-2.

4. The method of claim 1 , wherein said cytosolic translocation factor comprises Hsp 90.

5. The method of claim 1 wherein said cytosolic translocation factor comprises TrR-1.

6. The method of claim 1 , wherein measuring said translocation comprises measuring the ADP-ribosylation of elongation factor-2.

7. The method of claim 1 , wherein said toxin Diphtheria toxin.

8. A method of identifying a compound that is capable of promoting cell death in a mammal comprising the following steps:

a) isolating, from a mammalian cell, an early endosome comprising a toxin selected from the group consisting of Diptheria toxin, Botulinum toxin, Anthrax toxin Lethal Factor (LF), and Anthrax toxin Edema Factor (EF);

b) placing said endosomes in a cytosolic buffer;

c) contacting said endosomes with a cytosolic translocation factor complex, comprising beta-COP;

d) contacting said endosomes with said compound;

e) acidifying said endosome; and

f) measuring translocation of said toxin, wherein a decreased level of said translocation relative to that observed in the absence of said compound indicates that said compound is capable of promoting said cell death.

9. The method of claim 8 , wherein said toxin is a fusion protein comprising IL-2.

10. The method of claim 9 , wherein said fusion protein is DAB 389 IL-2.

11. The method of claim 8 , wherein said cytosolic translocation factor comprises Hsp 90.

12. The method of claim 8 , wherein said cytosolic translocation factor comprises TrR-1.

13. The method of claim 8 , wherein measuring said translocation comprises measuring the ADP-ribosylation of elongation factor-2.

14. The method of claim 8 , wherein said toxin is Diphtheria toxin.

15. The method of claim 8 , wherein said toxin is Botulinum toxin.

16. The method of claim 8 , wherein said toxin is Anthrax toxin Lethal Factor (LF).

17. The method of claim 8 , wherein said toxin is Anthrax toxin Edema Factor (EF).

18. The method of claim 8 , wherein said mammalian cell is a human cell.

19. The method of claim 1 , wherein said toxin is Botulinum toxin.

20. The method of claim 1 , wherein said toxin is Anthrax toxin Lethal Factor (LF).

21. The method of claim 1 , wherein said toxin is Anthrax toxin Edema Factor (EF).

22. The method of claim 1 , wherein said mammalian cell is a human cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 25, 2022
From: BOSTON UNIVERSITY MEDICAL CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 059697/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2006
From: MURPHY, JOHN R.; RATTS, RYAN
To: BOSTON MEDICAL CENTER CORPORATION
Reel/Frame 017320/0308 →
Continuity (3)
Continuation In Part PCTUS200400982900 · Mar 31, 2004
Provisional Application 6045918500 · Mar 31, 2003
Related Publication 20070238670A1 · Oct 11, 2007